HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamotte, M. Articles by Masure, J. Search for Related Content PubMed PubMed Citation Articles by Lamotte, M. Articles by Masure, J. Social Bookmarking                What's this?

A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients

¹ Health Economics and Disease Management, Meise, Belgium
² University of Ghent, Ghent, Belgium
³ Roche Pharmaceuticals, Brussels, Belgium

OBJECTIVES—Obesity is a common condition in type 2 diabetic patients. Treating obesity may enhance hypoglycemic treatment and contribute to the reduction of long-term microvascular and macrovascular complications. Orlistat reduces cardiovascular risk factors in obese type 2 diabetic patients. The objectives of this study were to estimate the long-term clinical consequences of this weight loss and the resulting cost-effectiveness of treating obese type 2 diabetic patients with orlistat.

RESEARCH DESIGN AND METHODS—A Markov model was developed to predict, over a 10-year period, the complication rates and mortality with and without a 2-year orlistat treatment, assuming a 5-year catch-up period after treatment. A stepwise approach was used to obtain the clinical data. First, the impact of weight loss with orlistat on HbA_1c, blood pressure, and cholesterol was assessed; then, the impact on mortality and micro- and macrovascular complications of decreasing these risk factors was applied. Four subgroups were studied based on the presence of risk factors.

RESULTS—Cost-effectiveness varies between 3,462 Euro/life-year gained (LYG) for obese diabetic patients with hypertension and hypercholesterolemia and 19,986 Euro/LYG for obese diabetic patients without other risk factors. The latter result is not robust according to sensitivity analyses.

CONCLUSIONS—Our results suggest that orlistat is cost-effective in the management of obese type 2 diabetic patients, especially in those with the presence of hypercholesterolemia and/or hypertension. Evidence on longer-term benefits of orlistat (>2 years) will be of importance for future decision-making.

Abbreviations: AHT, arterial hypertension • HHS, Helsinki Heart Study • LY, life year • LYG, LY gained • MI, myocardial infarction • UKPDS, U.K. Prospective Diabetes Study

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Lean and N. Finer ABC of obesity. Management: part II--drugs. BMJ, October 14, 2006; 333(7572): 794 - 797. [Full Text] [PDF]

				H. S. Brown III, J. K. Estrada, G. Hazarika, and E. Bastida Diabetes and the Labor Market: The community-wide economic cost in the Lower Rio Grande Valley Diabetes Care, December 1, 2005; 28(12): 2945 - 2947. [Full Text] [PDF]

				J. Edelsberg, D. Weycker, and G. Oster Response to Lamotte et al. Diabetes Care, October 1, 2002; 25(10): 1899 - 1900. [Full Text]

				D. E. Kelley, G. A. Bray, F. X. Pi-Sunyer, S. Klein, J. Hill, J. Miles, and P. Hollander Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes: A 1-year randomized controlled trial Diabetes Care, June 1, 2002; 25(6): 1033 - 1041. [Abstract] [Full Text] [PDF]